NCT00054730View on ClinicalTrials.gov

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2002

Conditions
Fragile X SyndromeAutism
Interventions
DRUG

CX516 (Ampalex®)

Trial Locations (2)

60612

RUSH-Presbyterian-St. Luke's Medical Center, Chicago

95817

UC Davis-MIND Institute, Sacramento

Sponsors

Collaborators (1)

FRAXA Research Foundation
All Listed Sponsors
collaborator

FRAXA Research Foundation

OTHER

lead

RespireRx

INDUSTRY